GLUE
Monte Rosa Therapeutics, Inc.
Latest Form 4:Sale$220KbyWarmuth Markus (President & CEO) · filed Jul 17, 2026
Monte Rosa Therapeutics, Inc. (GLUE) has 32 SEC Form 4 filings (62 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 17, 2026.
The most active filer is President & CEO Warmuth Markus with 7 filings. Insiders have net sold $3.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Markus Warmuth
- Employees:142
- HQ:Boston, MA, US
- IPO:2021-06-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$1.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President & CEO | Sale | 9,500 | $220K | Jul 17 | SEC ↗ | |
| Chief Operating Officer | Sale | 4,351 | $102K | Jul 16 | SEC ↗ | |
| Chief Scientific Officer | Sale | 6,000 | $140K | Jul 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,407 | $132K | Jul 1 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,000 | $138K | Jun 30 | SEC ↗ | |
| Director | Sale | 10,000 | $231K | Jun 30 | SEC ↗ | |
Janku FilipFirst in 4 months | Chief Medical Officer | Sale | 11,845 | $240K | Jun 25 | SEC ↗ |
Janku FilipFirst in 4 months | Chief Medical Officer | Sale | 30,000 | $643K | Jun 25 | SEC ↗ |
| Chief Scientific Officer | Sale | 3,000 | $60K | Jun 25 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,175 | $44K | Jun 25 | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,000 | $57K | Jun 18 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,176 | $41K | Jun 18 | SEC ↗ | |
| President & CEO | Sale | 5,466 | $106K | Jun 2 | SEC ↗ | |
Townson SharonFirst in 5 months | Chief Scientific Officer | Sale | 6,000 | $119K | Jun 1 | SEC ↗ |
| Chief Operating Officer | Sale | 2,175 | $44K | May 28 | SEC ↗ | |
Champoux JenniferFirst in 5 months | Chief Operating Officer | Sale | 2,176 | $41K | May 26 | SEC ↗ |
Manning Anthony M.First filing | Director | Sale | 10,000 | $180K | May 22 | SEC ↗ |
| President & CEO | Sale | 5,467 | $103K | May 5 | SEC ↗ | |
| President & CEO | Sale | 8,000 | $141K | Apr 15 | SEC ↗ | |
Nickson PhilipFirst in 3 months | Chief Business & Legal Officer | Sale | 5,845 | $103K | Apr 10 | SEC ↗ |
| Principal Accounting Officer | Sale | 139 | $2K | Mar 5 | SEC ↗ | |
| President & CEO | Sale | 5,466 | $98K | Mar 4 | SEC ↗ | |
| Principal Accounting Officer | Sale | 25,164 | $456K | Mar 2 | SEC ↗ | |
| Principal Accounting Officer | Sale | 536 | $9K | Mar 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 9,189 | $179K | Feb 24 | SEC ↗ | |
| President & CEO | Sale | 5,466 | $128K | Jan 9 | SEC ↗ | |
Townson SharonFirst filing | Chief Scientific Officer | Sale | 3,155 | $48K | Jan 5 | SEC ↗ |
Warmuth MarkusFirst filing | President & CEO | Sale | 10,135 | $154K | Jan 5 | SEC ↗ |
Janku FilipFirst filing | Chief Medical Officer | Sale | 3,155 | $48K | Jan 5 | SEC ↗ |
Nickson PhilipFirst filing | Chief Business & Legal Officer | Sale | 3,155 | $48K | Jan 5 | SEC ↗ |
Champoux JenniferFirst filing | Chief Operating Officer | Sale | 2,629 | $40K | Jan 5 | SEC ↗ |
Dunn EdmundFirst filing | Principal Accounting Officer | Sale | 1,039 | $16K | Jan 5 | SEC ↗ |
Related companies
Monte Rosa Therapeutics, Inc. is in the Healthcare sector.